# Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension

> **NCT01642446** · NA · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 160 (actual)

## Conditions studied

- Hepatocellular Carcinoma(HCC)
- Cirrhotic Portal Hypertension

## Interventions

- **PROCEDURE:** Precise hepatectomy
- **OTHER:** Combined intervention (chemoembolization/ablation)

## Key facts

- **NCT ID:** NCT01642446
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2018-12-30
- **Final completion:** 2021-08-30
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2021-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01642446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01642446, "Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01642446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*